April 16, 2014 Ajinomoto Pharmaceuticals Co., Ltd. Phase 2a Clinical Study Data of AJM300, an Oral 4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014

First Page		Document Content
Date: 2014-04-14 23:44:58		April 16, 2014 Ajinomoto Pharmaceuticals Co., Ltd. Phase 2a Clinical Study Data of AJM300, an Oral 4 Integrin Antagonist, Will Be Presented in Digestive Disease Week 2014 Add to Reading List Source URL: www.ajinomoto-seiyaku.co.jp Download Document from Source Website File Size: 163,99 KB Share Document on Facebook